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The Longitudinal Pattern of Response When Morphine
Is Used To Treat Chronic Refractory Dyspnea
David C. Currow, BMed, MPH, FRACP,1 Stephen Quinn, PhD,2 Aine Greene, RN, FRCNA,3 Janet Bull, MD,4
Miriam J. Johnson, MB, ChB, MD, FRCP, MRCGP,5 and Amy P. Abernethy, MD1,6
Abstract
Background: While evidence supports using sustained release morphine for chronic refractory breathlessness,
little is known about the longitudinal pattern of breathlessness intensity as people achieve symptomatic benefit.
The aim of this study is to describe this pattern.
Methods: This secondary analysis used breathlessness intensity scores (100mm visual analogue scale (VAS))
from a prospective, dose increment study of once daily (morning) sustained release morphine for chronic
refractory breathlessness. Participants who achieved < 10% improvement over their own baseline at one week
(10mg) were titrated to 20mg and if no response, another week later to 30mg for one week. Time was stan-
dardized at the first day of the week in which participants responded generating twice daily data one week
either side of symptomatic benefit. Analysis used random effect mixed modeling.
Results: Of the 83 participants, 17/52 responders required > 10mg: 13 participants (20mg) and 4 (30mg),
contributing 634 VAS observations. In the week leading to a response, average VAS scores worsened by 0.3mm/
day ( p = 0.16); the average improvement in the first 24 hours of response was 10.9mm (7.0 to 14.7; p < 0.0001),
with continued improvement of 2.2mm/day ( p < 0.001) for six more days.
Conclusion: When treating chronic refractory breathlessness with once daily sustained release morphine, titrate to
effect, since inadequate dose may generate no response; and following an initial response, further dose increases
should not occur for at least one week. Whether further benefit would be derived beyond day six on the dose to
which people respond, and what net effect a further dose increase would have are questions yet to be answered.
Introduction
Many diseases are associated with chronic breath-lessness that no longer respond to disease-modifying
therapies (chronic refractory breathlessness).1 Internationally,
there are no medications registered with regulatory agencies
for reducing symptomatic breathlessness, despite the burden
seen across the community.2,3 Across the population, the
prevalence and intensity of breathlessness both increase as
death approaches.4,5
Level I evidence supports the use of morphine for reducing
the subjective sensation of breathlessness.1,6 More recently,
these studies have been complemented by a phase IV study
confirming that the net benefits are sustained over time
without further dose increases7 and identifying people whose
breathlessness is most likely to respond to opioids.8 Recent
laboratory studies are also helping in defining the role of
opioids in modulating breathlessness.9,10 Recommendations
from the American Thoracic Society and the American Col-
lege of Physicians for the clinical management of refractory
breathlessness now include the use of opioids.11,12
Phase II dose-ranging data can help to understand how
people’s breathlessness intensity responds to morphine, thus
informing how best to titrate morphine in this population.
Possibilities include a progressive dose/response relationship
or a cumulative dose theshold at which people respond.
In a recently published study, sustained release morphine
administered orally once daily (morning) to people with
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chronic refractory breathlessness was titrated to effect using a
set algorithm.7 The starting dose was 10mg and each week an
additional 10mg/day was administered if participants did
not achieve at least a 10% reduction over their own baseline
breathlessness intensity and did not experience unacceptable
side effects. The study demonstrated that over 60% of par-
ticipants (52/83) with chronic refractory breathlessness re-
sponded symptomatically to sustained release morphine,
requiring either 10mg/day (n = 35), 20mg/day (n = 13), or
30mg/day (n = 4). This current substudy used data from the
latter two groups where data for a full week before and after
responses were available when measured by morning and
evening 100mm visual analogue scales (VAS). The aim of this
analysis was to describe the pattern of response for breath-
lessness intensity in order to inform dose titration in people
who have responded in routine clinical care.
Material and Methods
Study design
The primary study in chronic refractory breathlessness was
a prospective, open-label phase II/IV study of once daily
(morning) sustained release morphine (KapanolR, KadianR),
together with sodium docusate with sennosides to help treat
morphine-induced constipation.7 Morning and evening scores
for breathlessness intensity ‘‘right now’’ were averaged for the
last three days of eachweek of treatment. The starting dosewas
10mg sustained release morphine each morning; participants
whose breathlessness intensity had not reduced by at least 10%
over their own baseline at one week were titrated up by 10mg
each week to a maximum dose of 30mg/day.
In this analysis we created a standardized point in time by
using the first day of the week in which the 17 people who
required a dose greater than 10mg daily achieved their > 10%
reduction in breathlessness intensity (see Figure 1). This cor-
responded to day 8 for those who gained symptomatic benefit
with 20mg (n = 13) of sustained release morphine and day 15
for those who required 30mg (n = 4).
Study participants
Participants were opioid-naı¨ve outpatients aged ‡ 18 years
with ongoing breathlessness scored at ‡ 3 on the modified
Medical Research Council (mMRC) scale (see Table 1).13–15 To
be eligible, all underlying reversible causes of the breathless-
ness must have been maximally treated as judged by the
participant’s relevant physician (e.g., a pulmonologist for a
participant with chronic obstructive pulmonary disease, a
cardiologist for someone with heart failure). All medications
including oxygen must have been stable for the seven days
before commencing the study, and clinician-estimated life
expectancy must have been greater than one month.
Exclusion criteria included regular use of any opioid
medication or monoamine oxidase inhibitor in the two weeks
before screening; a true hypersensitivity reaction tomorphine;
a history of substance misuse; performance status £ 40 on the
Australian-modified Karnofsky Performance scale (AKPS) at
baseline;16 severe renal impairment (a calculated creatinine
clearance of £ 15ml/min/1.73m2 using the Modification of
Diet in Renal Disease (MDRD) formula);17,18 pregnancy; or
poor cognition (less than 24/30 on a Mini-Mental State
Examination (MMSE)).19
Setting
Participants were recruited from four university teaching
hospitals in two Australian states between July 2007 and
October 2009, with follow-up data collection ceasing in
January 2010.
Measurements
Intensity of breathlessness was recorded morning and
evening in participant diaries measured on 100mm VAS an-
chored at 0mm (‘‘no breathlessness’’) and at 100mm (‘‘worst
imaginable breathlessness’’). The question referred to
breathlessness ‘‘right now.’’ Breathlessness was measured
twice daily (morning and evening) with at least 17 days of
data (34 observations) per participant in this subgroup of
17. Other measures included demographic and clinical
data, the McGill Quality of Life Questionnaire, and functional
status.20
FIG. 1. Patient flow through the dose-ranging/long-term
therapy study for sustained release morphine for the re-
duction in chronic refractory breathlessness. Participants
who are the subject of this sub study.
Table 1. Modified Medication Research Council
Scale (mMRC)15
Grade Description of breathlessness
0 I only get breathless with strenuous exercise.
1 I get short of breath when hurrying on level ground
or walking up a slight hill.
2 On level ground, I walk slower than people of the
same age because of breathlessness, or have to
stop for breath when walking at my own pace.
3 I stop for breath after walking about 100 yards or after
a few minutes on level ground.
4 I am too breathless to leave the house or I am
breathless when dressing.
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Statistical methods
Differences between the groups at the two dose levels were
compared using v2 or t-tests as appropriate. Changes in VAS
were analyzed using random effect mixed modeling to ac-
count for correlated readings within an individual. The cov-
ariates were day of trial; response; the interaction term
‘‘day*response;’’ age; gender; chronic obstructive pulmonary
disease (COPD; yes/no); and AKPS. For each participant, the
day was synchronized so that day zero corresponded to the
first day of the week with the highest incremental dose re-
ceived. Residuals at each level were inspected for normal-
ity and linearity. There was no evidence of model violation.
A p-value of 0.05 (two-tailed) was considered statistically
significant. All analyses were performed using Stata statistical
software version 12.0 (StataCorp., College Station, TX).
Ethics, consent, and trial registration
The researchwas approved by all participating institutions’
research and ethics committees. All participants pro-
vided written informed consent. The study received clinical
trials notification approval to use KapanolR for an unregis-
tered indication. The trial was registered with the Australian
and New Zealand Clinical Trials Registry (ACTRNO-
12606000269538).
Results
Participant flow and study population
Eighty-three people participated in the original study for a
mean of 142 days (median 29; range 2–665). Thirty-five de-
rived benefit at 10mg/day sustained release morphine; 17
participants responded at higher dose (this substudy); and 31
derived no net benefit. Reasons for no net benefit included no
benefit at themaximumdose of 30mg (n = 8), lacked benefit at
lower doses and withdrew (n= 3), unacceptable side effects
(n = 15), death unrelated to the intervention (n = 4), or clinician
request (n = 1).
Of the 17 participants requiring a higher dose for response,
eight (47%) were male and nine (53%) had COPD as the un-
derlying cause of breathlessness (see Table 2). Age ranged
from 63 to 88 (median 82; interquartile range 73–83); and
median AKPS was 60 (range 50–80). The four participants
who responded at doses of 30mg were significantly older
(mean age 80.2 years) than the 13 participants who responded
at a dose of 20mg (mean age 71.2 years; p = 0.042). There were
no other differences between the groups.
Individuals responding to 20mg and 30mgwere combined
to evaluate the curve of response before and after the dose
increment (see Figure 2). Using all of the variables outlined,
three distinct phases were seen: (1) a plateau phase in the
week preceding response; (2) an immediate and significant
reduction in breathlessness scores at initial response (mean
absolute reduction 10.9mm (95% confidence interval (CI) 7.0
to 14.7 ( i < 0.001; relative reduction 21.0%) in the first 24 hours
of response after dose increment compared to the minimum
VAS reading on the previous incremental dose; and (3) a
phase of continued improvement of breathlessness daily over
the following six days of 2.2mm per day (95% CI 1.3 to 3.2;
i < 0.001).
By the end of the week after the initial response, the mag-
nitude of response had doubled compared with the response
seen in the first 24 hours (see Figure 2).
Performance status as a potential confounder on the lon-
gitudinal trends was explored. The interaction between
breathlessness and performance status demonstrated that as
performance status worsened, intensity of breathlessness in-
creased. For every 10 unit decrease in AKPS, VAS increased
by 16mm. No other confounders were identified.
Discussion
This is the first study to document breathlessness intensity
on a daily basis in people who responded to sustained release
morphine for chronic refractory breathlessness. The temporal
course of the reduction in breathlessness in response to
treatment is important to inform both clinical management
and future research to refine the place of morphine for the
management of breathlessness. These data suggest that when
people’s refractory breathlessness responds to sustained re-
lease morphine, there is a rapid and marked decline in the
intensity of breathlessness. There is further reduction in in-
tensity in the ensuing week that doubles the response of the
first 24 hours of response and provides guidance for the in-
terval before further dose increases.
In chronic refractory breathlessness, the reduction in the
intensity required to be clinically meaningful is approxima-
tely 10mm on a VAS.21–28 In this study, those who respond
have, on average, twice that reduction (19.8mm) after a fur-
ther week at the same dose.
Table 2. Baseline Mean (SD) or N (%) Demographic
Data by Morphine Dose
20mg
(n = 13)
30mg
(n = 4)
P-value
(Difference)
Age in years (mean) 80.2 (6.5) 71.5 (8.2) 0.04
Male sex 5 (38.5) 3 (75.0) 0.29
Performance status
(AKPS)
1.0
50 2 1
60 6 2
70 4 1
80 1 0
COPD 7 (53.9) 2 (50.0) 1.0
AKPS, Australian–modified Karnofsky Performance Status scale;
COPD, Chronic Obstructive Pulmonary Disease.
FIG. 2. Crude vs. predicted change in VAS per day.
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Response in thewhole study population and in this substudy
was independent of underlying etiology of breathlessness
(COPD or not), providing additional support to the notion of a
‘final common pathway’ generating the perception of breath-
lessness.8 The concept that benefit from morphine in reducing
the intensity of breathlessness may be seen in a range of un-
derlying etiologies is currently being explored in phase III
double-blind, randomized trials.
The finding of a relationship between performance status
and breathlessness is consistent with other data that suggest
that breathlessness worsens as death approaches.4,5 It will be
important in future work to define whether the relationship
between breathlessness and disease trajectory is linear or
whether there is an accelerated late phase.
Limitations of the study
These results may underestimate the net clinical benefit,
since the minimum VAS in the week preceding the successful
dose increment was the anchor point for the calculations and
hence was the most conservative model. Using either the
average or highest VAS in that week would demonstrate a
more dramatic response. The longitudinal period explored
after the dose increment was only a week, and continued
decline in breathlessness intensity was observed on all days.
Understanding whether there was continued reduction in
breathlessness intensity beyond that point is crucial.
Data from this dose titration and pharmacovigilance study
do not inform how quickly upward titration of sustained re-
lease morphine can occur until a symptomatic response, al-
though this is likely to be much less than one week. The data
only refer to the symptomatic improvement after initial re-
sponse, suggesting that further titration should be limited to
the time when benefit is maximized. If there are parallels
between pain and breathlessness, it is of note that the one
study in pain that has looked at rapid titration found that
initiating therapy with immediate release oral morphine so-
lution reached steady doses no more quickly than controlled
release morphine.29 The current study suggests that the con-
tinuing increase in symptom control after a regular dose of
morphine has been established should be further studied in
both pain and breathlessness.
Another important potential confounder in studies of
the management of symptoms such as breathlessness or pain
as they relate to the level of function is that people may
increase activity as the symptom is better controlled. If the
exertional threshold at which breathlessness becomes trou-
blesome can be raised, people’s exercise tolerance may in-
crease while they still report troublesome breathlessness as
that (higher) threshold is reached. Supporting this theory,
a study of people with COPD appears to show that exer-
cise tolerance improved with fentanyl, when compared
with placebo, but breathlessness intensity scores were un-
changed.30 As such, future work in this area needs to have a
more objective level of understanding of clinically mean-
ingful day-to-day improvements in function over the per-
son’s own baseline either through more frequent use of
validated tools (e.g., Lifespace) or direct measurement using
actigraphs.31–33 Given the interplay between exercise, mus-
cle function, and breathlessness intensity, function should be
measured in future studies of the symptomatic measurement
of breathlessness.34
Although the number of participants included in this sub-
study is relatively small (n = 17), participants provided many
observations (634 observations in total). As a result, these are
statistically significant results that are clinically relevant. The
McGill quality of life questionnaire and AKPS were only
sought weekly.16,20 When recorded more frequently in future
studies (daily for AKPS, second daily for McGill) it will be
important to see if and when they shift in relation to the
documented reduction in breathlessness.
Generalizability
The findings usefully inform clinicians how to safely titrate
sustained releasemorphine. Thismultisite study reports people
whose unifying feature is the intensity of their breathlessness.
The level of breathlessness seen at baseline in this current study
is of the same order of magnitude as several recent studies in
refractory breathlessness.6,35 This supports the generalizability
of these findings to a range of clinical settings.
Implications for clinicians and policymakers
Current practice in the use of morphine for breathlessness
does not recommend titration to benefit or toxicity, although
this approach is familiar in pain management. This study, as
one aspect of the information needed in a full pharmacody-
namic profile of morphine for chronic refractory breathless-
ness, adds a new dimension to the titration of sustained
release morphine. After a dramatic reduction in breathless-
ness, there appears to be continued improvement in levels of
breathlessness for at least one week. Titration within that time
would increase the likelihood of toxicity, as the maximal
benefit may not have been achieved.
Future research
The magnitude of improvement beyond the first seven
days is unknown, as the data are not available. The question
of whether further reductions in breathlessness could be
achievedwith further dose increases andwithout unacceptable
toxicities has not been answered. Blinding this increment in an
enriched cohort design would improve the level of evidence
generated by the findings. As noted above, the McGill Quality
of Life questionnaire, objective measures of activity, self-
reported activities of daily living need to be measured more
frequently in any subsequent study. An optimally designed
study would include measurement of both intensity and un-
pleasantness of breathlessness, given recent evidence that these
dimensions of breathlessness have different trajectories.36 For
safety, noninvasive measurement of the partial pressures of
oxygen and carbon dioxide is necessary.
Conclusion
Continued effort to understand how to optimize prescribing
of sustained release morphine for chronic refractory breath-
lessness is a clinical priority. This analysis focuses on the in-
creasing benefits seen days after an initial response, informing
directly the timing of any subsequent upward titration.
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